Characteristics of patients with SMNs
| SMNs (n = 45) . | |
|---|---|
| CAR T-cell product | |
| Axi-cel | 26 (57.8) |
| Tisa-celx`` | 9 (20.0) |
| Liso-cel | 10 (22.2) |
| Histologic subtype | |
| DLBCL | 22 (48.9) |
| Transformed FL | 14 (31.1) |
| PMBCL | 1 (2.2) |
| Richter | 2 (4.0) |
| Gray zone | 1 (2.2) |
| Other | 3 (6.6) |
| Molecular rearrangements by FISH | |
| C-MYC | 6 (13.3) |
| BCL-2 | 9 (20.0) |
| BCL-6 | 6 (13.3) |
| Double hit | 3 (6.7) |
| Prior tobacco use | 14 (31.1) |
| EBER positive | 0 |
| HIV positive∗ | 0 |
| Autoimmune disease | 2 (4.4) |
| Median prior lines of therapy (range) | 3 (2-7) |
| Prior stem cell transplantation | |
| Autologous | 25 (55.6) |
| Allogeneic | 2 (4.4) |
| Bridging therapy, n = 27 | |
| Steroids alone | 3 (11.1) |
| Rituximab ± steroids | 1 (3.7) |
| Chemotherapy ± rituximab or steroids | 9 (33.3) |
| Lenalidomide ± rituximab or steroids | 2 (7.4) |
| Obinutuzumab ± rituximab or steroids | 2 (7.4) |
| Polatuzumab- BR | 4 (14.8) |
| BTK-I ± venetoclax | 3 (11.1) |
| Other | 3 (11.1) |
| Best response to therapy | |
| CR | 32 (71.1) |
| PR | 5 (11.1) |
| SD | 1 (2.2) |
| PD | 4 (8.9) |
| NE | 3 (6.7) |
| SMN | |
| MDS | 18 (40.0) |
| Solid tumor | 11 (24.4) |
| AML | 6 (13.3) |
| Cutaneous (BCC/SCC) | 5 (11.1) |
| PTCL | 1 (2.2) |
| Other | 4 (8.9) |
| Median time from CAR T-cell infusion to SMN (range), mo | 19.3 (4.0-80.2) |
| SMNs (n = 45) . | |
|---|---|
| CAR T-cell product | |
| Axi-cel | 26 (57.8) |
| Tisa-celx`` | 9 (20.0) |
| Liso-cel | 10 (22.2) |
| Histologic subtype | |
| DLBCL | 22 (48.9) |
| Transformed FL | 14 (31.1) |
| PMBCL | 1 (2.2) |
| Richter | 2 (4.0) |
| Gray zone | 1 (2.2) |
| Other | 3 (6.6) |
| Molecular rearrangements by FISH | |
| C-MYC | 6 (13.3) |
| BCL-2 | 9 (20.0) |
| BCL-6 | 6 (13.3) |
| Double hit | 3 (6.7) |
| Prior tobacco use | 14 (31.1) |
| EBER positive | 0 |
| HIV positive∗ | 0 |
| Autoimmune disease | 2 (4.4) |
| Median prior lines of therapy (range) | 3 (2-7) |
| Prior stem cell transplantation | |
| Autologous | 25 (55.6) |
| Allogeneic | 2 (4.4) |
| Bridging therapy, n = 27 | |
| Steroids alone | 3 (11.1) |
| Rituximab ± steroids | 1 (3.7) |
| Chemotherapy ± rituximab or steroids | 9 (33.3) |
| Lenalidomide ± rituximab or steroids | 2 (7.4) |
| Obinutuzumab ± rituximab or steroids | 2 (7.4) |
| Polatuzumab- BR | 4 (14.8) |
| BTK-I ± venetoclax | 3 (11.1) |
| Other | 3 (11.1) |
| Best response to therapy | |
| CR | 32 (71.1) |
| PR | 5 (11.1) |
| SD | 1 (2.2) |
| PD | 4 (8.9) |
| NE | 3 (6.7) |
| SMN | |
| MDS | 18 (40.0) |
| Solid tumor | 11 (24.4) |
| AML | 6 (13.3) |
| Cutaneous (BCC/SCC) | 5 (11.1) |
| PTCL | 1 (2.2) |
| Other | 4 (8.9) |
| Median time from CAR T-cell infusion to SMN (range), mo | 19.3 (4.0-80.2) |
AML, acute myeloid leukemia; BCC, basal cell carcinoma; BCL-2, B-cell lymphoma 2; BR, bendamustine/rituximab; BTKi, Bruton tyrosine kinase inhibitor; CR, complete response; EBER, Epstein-Barr virus–encoded RNA; NE, not evaluable; PD, progressive disease; PMBCL, primary mediastinal B-cell lymphoma; PR, partial response; PTCL, peripheral T-cell lymphoma; SCC, squamous cell carcinoma; SD, stable disease.